We are interested in the heritable aspects of cancer with a focus on two cohort populations - the International Sarcoma Kindred Study (ISKS) and the Genetic Cancer Risk in the Young (Cancer Risk) Study. In addition, individuals are increasingly being identified by genotype (often in the absence of a family history) as having an elevated cancer risk. Our research includes the Surveillance in Multi-Organ Cancer prone syndromes (SMOC+) study that screens genotypically identified individuals regularly and follows up outcomes longitudinally.
We aim to understand further the genetic contribution to cancer risk and the implications of genotype identified risk. This will potentially more fully inform clinical surveillance strategies, treatment regimes, reproductive and lifestyle decisions and potentially improve outcomes for families affected by cancer.
Thomas DM, Ballinger ML. Diagnosis and Management of Hereditary Sarcoma. Recent Results Cancer Res. 2016; 205:169-89.
Thomas DM, James PA, Ballinger ML. Clinical implications of genomics for cancer risk genetics. Lancet Oncol. 2015 Jun;16(6):e303-8.
Ballinger ML, Mitchell G & Thomas DM, Surveillance recommendations for patients with germline TP53 mutations, Current Opinion in Oncology 2015; 27(4): 332-337
Thomas DM and Ballinger ML, Advances in genetic testing for hereditary sarcoma. In: Diagnosis and management of hereditary cancer. Eds Chris Jacobs and Gabriella Pichert. Springer 2015 (in press)
Thomas DM & Ballinger ML, Etiologic, environmental and inherited risk factors in sarcomas, Journal of Surgical Oncology 2015; 111: 490-495
Thomas DM, James PA, Ballinger ML, Clinical implications of genomics for cancer risk genetics, Lancet Oncology 2015; 16:e3030-8
McBride KM, Schlub TE, Ballinger ML, Thomas DM, Tattersall MHN, An international survey of awareness of genetic risk in the clinical sarcoma community, 2015 (accepted Asia Pacific Journal of Clincal Oncology)
Mirabello L, Koster R, Moriarty BS et al, A genome-wide scan identifies variants in NFIB associated with metastasis in patients with osteosarcoma, Cancer Discovery 2015; 5(9): 920-31
McBride KA, Hallowell N, Tattersall MHN, Kirk J, Ballinger ML, Thomas DM et al, Timing and Context: important considerations in the return of genetic results to research participants, Journal of Community Genetics 2015; DOI 10.1007/s12687-015-0231-7
K McBride, ML Ballinger, E Killick, J Kirk, MHN Tattersall, RA Eeles , DM Thomas* & GM Mitchell* (*equal last author), Germline TP53 mutations and Li-Fraumeni Syndrome: an evidence-based approach to cancer risks and clinical management, Nature Reviews Clinical Oncology 2014; 11: 260-271
Mitchell G*, Ballinger ML*, Wong S, et al. High frequency of germline TP53 mutations in a prospective adult-onset sarcoma cohort. PLoS one 2013; 8 (7): e69026. *equal first author
Young M-A, Herlihy A, Mitchell G, Thomas DM, Ballinger ML, Tucker K, Lewis CR, Neuhaus S, International Sarcoma Kindred Study and Halliday J. The attitudes of people with sarcoma and their family towards genomics and incidental information arising from genetic research. Clinical Sarcoma Research 2013; 3:11
More Garvan Publications
Staff in the Group
In the News
Beyond ‘single-gene thinking’: Garvan researchers uncover complex genetic secrets of cancer risk - Aug 05, 2016